Share Name Share Symbol Market Type Share ISIN Share Description
Sphere Medical LSE:SPHR London Ordinary Share GB00B551W951 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 11.00p 10.50p 11.50p 11.00p 11.00p 11.00p 1,950 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -6.0 -4.8 - 15.59

Sphere Medical (SPHR) Latest News

More Sphere Medical News
Sphere Medical Takeover Rumours

Sphere Medical (SPHR) Share Charts

1 Year Sphere Medical Chart

1 Year Sphere Medical Chart

1 Month Sphere Medical Chart

1 Month Sphere Medical Chart

Intraday Sphere Medical Chart

Intraday Sphere Medical Chart

Sphere Medical (SPHR) Discussions and Chat

Sphere Medical Forums and Chat

Date Time Title Posts
27/10/201612:09SPHERE MEDICAL995
25/6/201508:10Sphere Medical post CE Marks....Sales ready for take off....16

Add a New Thread

Sphere Medical (SPHR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
View all Sphere Medical trades in real-time

Sphere Medical (SPHR) Top Chat Posts

Sphere Medical Daily Update: Sphere Medical is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker SPHR. The last closing price for Sphere Medical was 11p.
Sphere Medical has a 4 week average price of 11.29p and a 12 week average price of 11.42p.
The 1 year high share price is 14.50p while the 1 year low share price is currently 5p.
There are currently 141,757,872 shares in issue and the average daily traded volume is 12,364 shares. The market capitalisation of Sphere Medical is £15,593,365.92.
cc2014: Woodford 29.6% - initial stake March 2015 and have added regularly Wales Life Sciences 17.6% - initial stake March 2015 LSP Life Sciences 7.7% - have held 3-4 years and added in March 2015 Ortho-Clinical Diag 5.7% - have held 3-4 years Octopus 4.4% - initial stake March 2015 Ruffer 4.0% - have held 3-5 years and added in March 2015 Royal London 4.0% - have held 3-5 years and added in March 2015 Parkway Technology 2.4% - think acquired in last 6 months UBS 1.0% - acquired in Sept 15 Redmayne Bentley 0.9% - acquired in April 16 Oxford Capital 0.7% - have held 3-5 years Jarvis 0.8% - new position Mr. T. Robinson 2.3% - Not sure how long held (likely years) but bought more in April 16 Mr D. Norwood 0.8% - Not sure how long held (likely years) - appears to be reducing Artemis 0.6% - Held over a year but possibly reducing William Soloman 0.6% - Held a few months ago but not sure if still in Share Centre 3.1% TD Direct 0.6% Hargreaves Lansdown 2.5% Barclays 1.3% Directors 0.8% There are a few I know about that are small that I've haven't detailed. In addition there are some PI's who are long term holders using paper certificates. All in all this means the "free float" is about 5% of the total share capital given most of those holders aren't going to sell even if the share price moves dramatically. It was one of the things that attracted me to this share
del44: Tim..... You are correct...... Quote.... "I asked about the cash flow projection in the TD note and in particular their forecast for an additional £10M funding requirement in early 2017, they were particularly vague about where it might come from. Wolfgang said it could come from another equity based raise or from some other source. He instantly ruled out any kind of equity swap along the lines of Yorkville or Darwin (Death Spiral) but said he would not rule out some other form of secured debt. Alternatively the cash could come from an upfront deal if and when they sign up with a partner (or partners), although he did concede that in the medical device/diagnostic world this was not common practice (unlike the bio-techs with their drug partnerships with big pharma). When I asked for an example he couldn’t immediately provide one..............................He said that the large shareholders had expressed the view that they didn’t want to discuss fundraising at this point and the time to discuss follow on funding would be when P4 has been approved for Europe, sales had increased and Sphere have secured one or more partners for P4 commercialization (if this goes according to plan the share price should be significantly higher than it is now)." But still....there is wiggle room for alternative fund raising other then issuing more shares....
longshanks: FWIW - the technicals are looking positive. Not for everyone, but I like to use them as a means of establishing decent entry points. What has got my eye is that this is currently trading at a nice premium above a 200d moving average curve that has flattened out after a prolonged downward trend. I can't see CE approval being a problem and I would expect the market to start factoring in the imminent arrival of this rubber stamp and the fact that this should kick-start commercialisation proper. In this respect I expect the share price to make a decent recovery back into the low 20's over the next few months. I am not too happy, however, with the strong likelihood that a significant placing will be required to bring this to profitability; with this I expect vultures to be swooping overhead for some time and you could argue - why buy when there are such forces at work. The one thing adding speculative interest for me is that they could land a good licensing deal (almost out of the blue) once they gain CE approval for Proxima 4. If it came with significant upfront and milestone payments then such a deal would be transformational and lead the price into the mid 40's very quickly.
cumnor: First partner is important-they will have done their due diligence before committing staff and resources to this product-so this is quite positive and along with CE mark authorization it will be a big milestone. After that it boils down to how management play it, how reliable, cost effective and time saving (compared to the present situation it certainly is) the product is. If it meets these criteria-and things are looking positive-then further funding will not be an issue and key players will have either snapped the company up or funding from a much higher share price will take place as stakeholders in the field recognize the potential of the product long before advfn posters do. Therefore funding wont be an issue if, as it seems, this small company product(it is generally the Abbotts and J&Js of the world who innovate this kind of thing)works. It is a gamble as it is with any single product developer so my investment is modest. imo
farmsted: Woodford's investment is reflective in the share price
waterloo01: Note the 'Now in discussions' Proactive Investors' One2One Investor Forum this Thursday the 26th November in Mayfair where the executive directors of Sphere Medical (LON:SPHR), Utilitywise (LON:UTW) & soon to be listed GrooveME will be in attendance Sphere Medical (LON:SPHR - Market Cap: £16 million) Sphere Medical is a company specialising in the commercialisation and further development of innovative medical monitoring and medical diagnostic equipment. The company is now in discussions with potential partners that would help with the roll out of its breakthrough proxima blood monitoring device. These discussions represent a key milestone as the company transitions into a commercial organisation centred on serving its customers, growing revenues and moving towards profitability. Chief Executive Wolfgang Rencken will be at the forum to outline what share price catalysts potential investors should be on the look-out for.
ladyfarmer: From Proactive Investor: Sphere Medical likely to find plenty of potential partners for Proxima Share 15:18 30 Sep 2015 Twice as much: finnCap has a price target of 25.5p for Sphere, which is roughly double the current share price Sphere Medical likely to find plenty of potential partners for Proxima Proxima 3 is now being sold directly by the company's own sales team in four EU countries: UK, Germany, the Netherlands and Belgium. House broker finnCap expects Sphere Medical (LON:SPHR) to nail a commercialisation deal for Proxima 4 by the middle of next year. The broker had to revisit its forecasts after Ortho Clinical Diagnostics (OCD) decided last month not to get into bed with Sphere, leaving the AIM-listed company free to pursue commercial agreements with other potential partners. The company has already entered a number of discussions, finnCap observed, and noted that while many global diagnostics companies have a presence in blood gas analysis, many do not have a point-of-care device (PoC), and so would be interested in Proxima 4. With Woodford Patient Capital in its corner – the investment fund pumped £4mln into Sphere earlier this year – the company can afford to take its time in the negotiations and secure the best deal. According to the house broker, the medtech firm has enough cash to deliver on its plans through to the end of the first half of 2017. While reinstating its full year (FY) estimates for 2015 of adjusted underlying losses of £7.0mln on sales of £100,000, the broker has released 2016 forecasts, comprising an underlying loss of £7.4mln on sales of £300,000. Sphere is still in the early stages of the roll-out of Proxima 3, with the first commercial sale achieved in June of this year, and while a number of hospitals are currently evaluating the product, finnCap is not expecting any significant additional revenue for the rest of this year. “We estimate that sales growth will accelerate as we go into FY 2016E, particularly once Proxima 4 is launched,” said analysts Keith Redpath and Michal Cabadaj. The broker saluted the good progress made on bringing Proxima 4 to market; the next generation system incorporates additional analytes - chemical substances that are the subject of chemical analysis – and plugs into hospitals’ information systems. “This is expected to lead to more rapid market penetration, particularly as the extra analytes (glucose and sodium) could significantly expand the range of conditions for which monitoring with Proxima 4 is suitable,” finnCap asserts. Applying a discount rate of 15% and assuming a 2.0% growth rate beyond its 10-year forecast period – the company is tipped to be knocking on the door of break-even in 2019 – the company has arrived at a discounted cash flow-driven price target of 25.5p. The shares currently trade at half that level. John Harrington   
cc2014: Hi Del, I'm not really in agreement with regard to shareholders wanting out as an explanation for the weak share price. I'm more in favour every so often there are forced sellers as the FTSE drops and drops. It is commonplace for PI's to overcommit their assets on their hopes of jam tomorrow. I have noticed that for example that yesterday aligned with a really horrible drop on FTSE and in particular the mining and oil sector. I think it's simply a case of capitulation when PI's simply can't take the losses any longer With regard to your quote may I ask which broker you are using? I assume you are having to phone for a quote as it's way over NMS?
cc2014: That was a damp squib. No real news and no movement on the share price. Guess we will just wait for some more positive new
cc2014: Analysts say Sphere may be able to negotiate a better commercial deal. Sphere Medical Holding (LON:SPHR) said Ortho Clinical Diagnostics (OCD) had decided not to exercise its option to acquire the global commercialisation rights for Proxima 4, its blood monitoring system. It follows a change of focus and ownership at OCD, which has been taken over by the US private equity giant Carlyle Group. OCD’s decision may actually leave Sphere better placed to commercial the device, which has gained market traction in the UK and Europe under its third iteration. “We see this as an opportunity that we are now free to also explore commercial agreements with other interested parties that are well placed to sell into the critical care market,” chief executive Wolfgang Rencken told Proactive. Broker finnCap added: Many global diagnostics companies have a presence in blood gas analysis but do not have a point-of-care device so we believe there is likely to be much interest in Proxima 4.” The share price, up 3.3%, revealed the market to be generally relaxed about the latest developments. Not sure how they think the share price was up 3.3% but maybe this will generate some interest tomorrow
Sphere Medical share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20161027 18:46:39